Research and Markets: Encephalopathy - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/t6kcvk/encephalopathyglo) has announced the addition of the "Encephalopathy-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015" report to their offering.

Encephalopathy-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Encephalopathy.

A key objective of The report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Encephalopathy.

The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Encephalopathy.

SCOPE:

  • A snapshot of the global Market therapeutics scenario for Encephalopathy.
  • A review of the marketed products under prescription for Encephalopathy, regulatory information and marketing status.
  • Coverage of global patent coverage and detailed commentaries on the US patent challenges.
  • Graphical representation of investigational products for patent expiry and market exclusivities across the globe.

Key Topics Covered:

  • Indication Overview
  • Marketed Drugs
  • Marketed Details of Drugs by Application Type
  • Marketed Details of Drugs (NDA) by Marketing Status
  • Marketed Details of Drugs by Patent Expiration Timeline
  • Active Pharmaceutical Ingredient (API) Manufacturers Assessment
  • API Manufacturers by United States Drug Master File (US DMF) Status
  • API Manufacturers by US DMF Status (Drug Specific)
  • API Manufacturers in Europe by Country
  • API Manufacturers in India by State
  • API Manufacturers in China by Province
  • Marketed Details of Approved Drugs by Geography
  • Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
  • API Manufacturers by US DMF Status (Drug Specific)
  • Drugs Market Data and Forecasted Sales Figure (2012-2016)
  • Marketed Drugs for Encephalopathy
  • Drug Name
  • Drug Description
  • Global Active Pharmaceutical Manufacturers for Drug
  • Approval Status of Drug
  • Patent and Exclusivity Details for Drug
  • Company Profile and Financials
  • Phase III Drugs for Encephalopathy
  • United States Drug Master File (DMF)
  • Discontinued Drugs for Encephalopathy

For more information visit http://www.researchandmarkets.com/research/t6kcvk/encephalopathyglo

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals